ELUTIA INC. (ELUT) Form 10-Q — May 15, 2026
Elutia Inc. reported a net loss of $7.5 million for the three months ended March 31, 2026, driven by a $7.9 million loss from continuing operations. Net sales increased 5.5% year-over-year to $3.1 million, with Cardiovascular product sales surging 214% following the termination of a distributor agreement and a shift to direct sales. The company ended the quarter with $28.5 million in cash and equivalents, which management believes is sufficient to fund operations for at least the next 12 months.
Key figures
- Revenue
- 3114000
- Revenue Yoy
- 5.5%
- Cash Position
- 28488000
- R and d expense
- 1973000
- Litigation costs net
- 606000
- Sales and marketing expense
- 1480000
- Divestiture proceeds receivable
- 8000000
- Insurance receivable litigation
- 5348000
- Litigation contingent liability
- 8016000
- General and administrative expense
- 4091000
- Income from discontinued operations
- 425000
Price after filing
Close on the filing date to close N calendar days later (from $1.04). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.